Menü
You have to log in or sign up before you can proceed.
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Xencor to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting
Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting


Lantheus Holdings, Inc. (NASDAQ: LNTH) (the “Company”), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture

Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting


Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that two abstracts featuring data from clinical studies evaluating Rubraca® (rucaparib) in metastatic castration-resistant prostate cancer

6 of the Top 7 Global CROs Partner With Veeva to Run Faster Clinical Trials for Sponsors
6 of the Top 7 Global CROs Partner With Veeva to Run Faster Clinical Trials for Sponsors


Veeva Systems (NYSE: VEEV) today announced that 6 out of the top 7 global CROs have joined the Veeva Vault CDMS partner program. Accelerating clinical research is a top priority in the life

6 of the Top 7 Global CROs Partner with Veeva to Run Faster Clinical Trials for Sponsors
6 of the Top 7 Global CROs Partner with Veeva to Run Faster Clinical Trials for Sponsors


Veeva Systems (NYSE: VEEV) today announced that 6 out of the top 7 global CROs have joined the Veeva Vault CDMS partner program. Accelerating clinical research is a top priority in the life

Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day
Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021

Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium
Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium


February 4, 2021 -- Today, Illumina, Inc. (NASDAQ:ILMN) announced an agreement with the Belgian Society of Medical Oncology (BSMO) which is running a new national pilot to evaluate the use of

GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates


Regulatory News:



GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies

Epredia setzt Veeva MedTech-Lösungen zur Vereinheitlichung der Änderungskontrolle in den Bereichen Qualität und Regulierung ein
Epredia setzt Veeva MedTech-Lösungen zur Vereinheitlichung der Änderungskontrolle in den Bereichen Qualität und Regulierung ein


Veeva Systems (NYSE: VEEV) gab heute bekannt, dass Epredia, ein weltweit führender Anbieter im Bereich der Präzisionsdiagnostik für Krebs und Gewebe, die Anwendungen Veeva Vault Quality und Veeva

Quidel Opens New Manufacturing Facility to Mass Produce QuickVue® Rapid Antigen Tests for COVID-19
Quidel Opens New Manufacturing Facility to Mass Produce QuickVue® Rapid Antigen Tests for COVID-19


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced the opening

Chemed To Report Fourth-Quarter 2020 Earnings February 23, Related Conference Call To Be Held On February 24
Chemed To Report Fourth-Quarter 2020 Earnings February 23, Related Conference Call To Be Held On February 24


Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the fourth quarter ended December 31, 2020, on Tuesday, February 23, 2021, following the close of trading on

Epredia Adopts Veeva MedTech Solutions to Unify Change Control Across Quality and Regulatory
Epredia Adopts Veeva MedTech Solutions to Unify Change Control Across Quality and Regulatory


Veeva Systems (NYSE: VEEV) today announced that Epredia, a global leader in precision cancer and tissue diagnostics, is adopting Veeva Vault Quality and Veeva Vault RIM applications to automate

Epredia Adopts Veeva MedTech Solutions to Unify Change Control Across Quality and Regulatory
Epredia Adopts Veeva MedTech Solutions to Unify Change Control Across Quality and Regulatory


Veeva Systems (NYSE: VEEV) today announced that Epredia, a global leader in precision cancer and tissue diagnostics, is adopting Veeva Vault Quality and Veeva Vault RIM applications to automate

PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 3, 2021.



Fourth

Dexcom und Nick Jonas enthüllen den ersten Super Bowl-Werbespot und fordern eine bessere Versorgung von Menschen mit Diabetes
Dexcom und Nick Jonas enthüllen den ersten Super Bowl-Werbespot und fordern eine bessere Versorgung von Menschen mit Diabetes


DexCom, Inc. (NASDAQ:DXCM), der weltweit führende Anbieter von kontinuierlicher Blutzuckermessung für Menschen mit Diabetes, hat heute seinen allerersten Super-Bowl-Werbespot mit dem

Dexcom and Nick Jonas Unveil First-Ever Super Bowl Commercial, Calling for Better Care for People With Diabetes
Dexcom and Nick Jonas Unveil First-Ever Super Bowl Commercial, Calling for Better Care for People With Diabetes


DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, debuted today its first-ever Super Bowl commercial, starring multi-platinum recording

AMN Healthcare Achieves High Ranking in LGBTQ Corporate Equality Index
AMN Healthcare Achieves High Ranking in LGBTQ Corporate Equality Index


AMN Healthcare (NYSE: AMN) received a top ranking – 95 out of 100 – in the Human Rights Campaign Foundation’s 2021 Corporate Equality Index, the nation’s foremost survey measuring corporate

Simulations Plus Enters Agreement with Distributor in China: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Enters Agreement with Distributor in China


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it

Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, February 9, 2021.



In connection with the

Premier, Inc. Reports Fiscal-Year 2021 Second-Quarter Results: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Reports Fiscal-Year 2021 Second-Quarter Results


Premier, Inc. (NASDAQ: PINC) today reported financial results for the fiscal year (FY) 2021 second quarter ended December 31, 2020 and announced its fiscal 2021 financial guidance.



All results

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICShttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS


Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter 2020 and full-year 2020, raised 2021 guidance(4) for Adjusted diluted EPS(2) and provided 2021 financial guidance(4) for other

Premier Inc. President Michael J. Alkire to Succeed Susan DeVore as Chief Executive Officer: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. President Michael J. Alkire to Succeed Susan DeVore as Chief Executive Officer


Premier Inc. (NASDAQ: PINC) today announced that after nearly 18 years of distinguished service, Susan DeVore is retiring as the company’s chief executive officer and a member of its Board of

Vifor Pharma to propose Dr Alexandre LeBeaut as Board member: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma to propose Dr Alexandre LeBeaut as Board member


Regulatory News:



Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.



Jacques

Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Head of Development. Dr. Schott

DispatchHealth and Humana Team Up to Provide Hospital-Level Care in the Home: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
DispatchHealth and Humana Team Up to Provide Hospital-Level Care in the Home


Humana Inc., a leading health and well-being company, and DispatchHealth, a provider of in-home medical care, today announced an agreement to provide Humana members with access to an advanced level